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1. Background 
 
Adenocarcinomas of the pancreas are exocrine tumors, originate from ductal system, including 
two morphologically distinct entities: the ductal adenocarcinoma and mucinous adenocarcinoma. 
Ductal adenocarcinoma is by far the most frequent malignant tumor in the pancreas, 
representing at least about 90% of all pancreas cancers. It is associated with very poor 
prognosis, due to the fact that actually there are no any biological markers or diagnostic tools for 
identification of the disease at an early stage. Most of the time the disease is extensive with 
vascular and nerves involvement or with metastatic spread at the time of diagnosis (1). The 
median survival is less than 5% at 5 years, placing it, at the fifth leading cause of death by 
cancer in the world (2). The mucinous form of pancreatic adenocarcinoma is less frequent, and 
seems to have a better prognosis with about 57% survival at 5 years (1)(3)(4). 
Each morphologic type of pancreatic adenocarcinoma is associated with particular preneoplastic 
lesions. Two types of preneoplastic lesions are described: firstly, pancreatic intra-epithelial 
neoplasia (PanIN) which affects the small and peripheral pancreatic ducts, and the intraductal 
papillary-mucinous neoplasm (IPMN) interested the main pancreatic ducts and its principal 
branches. Both of preneoplastic lesions lead by different mechanisms to the pancreatic 
adenocarcinoma (1)(2)(3)(4)(5)(6)(7)(8)(9)(10).  
The purpose of our study consists in a retrospective analysis of various clinical and histo-
morphological parameters in order to assess a difference in survival between these two 
morphological types of pancreatic adenocarcinomas. 
 
1.2 Material and methods 
 
 We conducted a retrospective analysis including 35 patients, (20 men and 15 women), 
beneficed the surgical treatment for pancreas adenocarcinoma at the Surgical Department of 
University Hospital in Lausanne. The patients involved in our study have been treated between 
2003 and 2008, permitting at least 5-years mean follow up. For each patient the following 
parameters were analysed: age, gender, type of operation, type of preneoplastic lesions, TNM 
stage, histological grade of the tumor, vascular invasion, lymphatic and perineural invasion, 
resection margins, and adjuvant treatment. 
The results from these observations were included in a univariate and multivariate statistical 
analysis and compared with overall survival, as well as specific survival for each morphologic 
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subtype of adenocarcinoma. 
As a low number of mucinous adenocarcinomas (n=5) was insufficient to conduct a pertinent 
statistical analysis, we compared the data obtained from adenocarcinomas developed on PanIN 
with adenocarcinomas developed on IPMN including both, ductal or mucinous types. 
 
1.3 Result 
 
Our results show that adenocarcinomas developed on pre-existing IPMN including both 
morphologic types (ductal and mucinous form) are associated with a better survival and 
prognosis than adenocarciomas developed on PanIN. 
 
1.4 Conclusion 
 
This study reflects that the most relevant parameter in survival in pancreatic adenocarcinoma 
seems to be the type of preneoplastic lesion. The significant difference in survival was noted 
between adenocarcinomas developing on PanIN as compared to adenocarcinomas developed 
on IPMN precursor lesions. Ductal adenocarcinomas developped on IPMN present significantly 
longer survival than those developed on PanIN lesions (P value= 0,01). Therefore we can 
suggest that the histological type of preneoplastic lesion rather than the histological type of 
adenocarcinoma should be the determinant prognosis factor in survival of pancreatic 
adenocarcinoma. 
 
2. Introduction 
 
Pancreatic adenocarcinoma is currently the five leading cause of death by cancer in the world 
(2). This is explained in part by the silent development of the disease. The symptoms such as 
ictere or weight loss appear in advanced stages of disease (1). The pancreas is, due to its 
anatomic localisation, more difficultly accessible to screening techniques as compared for 
example to other organs such breast and colon. The new screening techniques such 
Endoscopic Retrograde Cholangio-Pancreatography (ERCP) allows evaluation of the biliary and 
pancreatic ductular system. However, it is an invasive technique leading to the risk of 
pancreatitis in more than 10% of cases (13). Most of the time the disease is discovered at a 
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relatively advanced stage, which explains the poor prognosis with the median survival being less 
than 5% at 5 years (1)(5). 
The various risk factors such age, smoking, ethylism, chronic pancreatitis, obesity and familiar 
history are known to predisposing pancreatic adenocarcinoma(1)(5). 
The pancreatic adenocarcinoma is usually associated with preneoplastic lesions. The 
classification of these lesions was for a long time complex, since there was no uniform 
consensus concerning their origins and their significance in the outcome of patients. In 2003 an 
official classification of pancreatic intraepithelial neoplasia (PanIN) and intracanalar papillary 
mucinous neoplasia (IPMN) was adopted (8). 
PanINs are peripheric lesions, affecting the small pancreatic ducts, less than 0,5 cm in diameter, 
involved always in conventional, ductal type adenocarcinoma. According to degree of dysplasia 
the PanIN lesions are grouped into 3 categories.(Table 1) 
IPMN lesions are less frequent than PanIN, and occur most often in the main pancreatic duct 
and its principal branches (3). As these lesions are larger than 0,5 cm in diameter,  they can be 
detected easily by Rx. The IPMNs are also characterized by significant production of mucin.  
Morphologically, IPMN present the papillary architecture (rarely flat), consisting of columnar 
epithelial cells with different degrees of dysplasia (8). As PanIN, IPMN appear to follow an 
adenoma-carcinoma sequence according to the degree of dysplasia as shown in Table 1. 
 There are three categories of IPMNs: low grade adenoma, borderline neoplasia, and carcinoma 
in situ (7). The prognosis of these lesions seem to be less severe than for PanIN. IPMN lesions 
lead to cystic formation with mucin production, and affected the large size ducts, permitting to be 
detected by conventional radiological techniques at a earlier stage (1)(8). They are classified in 
four histological subgroups, and in the most of cases, they evolve to the mucinous 
adenocarcinoma (1)(3))(7). 
The most common form is the intestinal type of IPMN. It represents a villous appearance similar 
to villous adenoma of the colon. It grows most of the time in the main duct of the pancreas. In 
case of progression, it will develop into a mucinous adenocarcinoma. The pancreatobiliary type 
is a rare form showing papillary structures and evolves toward the ductal adenocarcinoma. This 
type has a less well prognosis as compared to intestinal type. The oncocytic type seems to be 
similar to the pancreatobilary type with the presence of oncocytic epithelial features and papillary 
structures. The evolution of this lesion remains still unknown. The gastric type is lined by 
cylindrical epithelial cells look like gastric foveolar cells with glandular elements resembling to 
pyloric glands at the top of the papillae. It seems that this type of IPMN lesion is the less 
aggressive (7).  
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2.2 Table 1: Nomenclature of preneoplastic lesions 
 
PanIN-1A:  
(Pancreatic Intraepithelial Neoplasia 1-A): flat lesion, tall columnar cells, 
basally located nuclei, abundant supranuclear mucin, small nuclei round to 
oval in shape.  
PanIN-1B: papillary, micropapillary or basally pseudostratified architecture, but                   
are otherwise identical to PanIN-1A.                                                              
 
PanIN-2: mucinous epithelial lesions flat or papillary, have some nuclear abnormalities such as loss of polarity, 
nuclear crowding, enlarged nuclei, pseudo-stratification and hyperchromatism. 
Mitoses are rare, but when present not apical and not atypical.  
 
PanIN-3: papillary or micropapillary, cribriforming, budding loss of nuclear 
polarity, dystrophic goblet cells abnormal mitoses nuclear irregularities and 
prominent nucleoli. 
 
IPMN adenoma: tall columnar epithelium with mucin-containing cells slight or 
no atypia. 
 
IPMN borderline: moderate dysplasia, papillary areas and pseudopapillary 
structures. 
 
 
Intraductal papillary mucinous carcinoma: severe dysplasia (carcinoma in 
situ) absence of invasion, with papillary or miocropapillary patter, cribiform 
growth and budding of small clusters of epithelial cells lack of mucin. 
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Usually it is not difficult to distinguish the PanIN from the IPMN lesions, because of their different 
sizes and localization. However, the distinction can be sometimes difficult, as the gastric type 
IPMN, for example, may extend to small ducts, and inversely some PanIN lesions can extend 
into the main and branches pancreatic ducts (8). 
It is not uncommon for the IPMN lesions to develop into a ductal adenocarcinoma (8). However it 
may be possible to distinguish the initial preneoplastic lesion by its particular immunophenotype.  
Both types of lesions (PanIN and IPMN) produce mucin, which is a glycoprotein of high 
molecular weight. Mucin profile is different in these two lesions and may be of particular interest 
to distinguish various histological types of ductal pancreatic neoplasia.  
MUC1 is essentially expressed in PanIN lesions, and its expression increases with the severity 
of dysplastic changes leading to ductal adenocarcinoma. Expression of MUC1 is associated with 
poor prognosis. MUC2 is more characteristic for IPMN lesions. However the gastric type of 
IPMN express MUC1 and not MUC2 and in this case the difference between PanIN and IPMN is 
more difficult (1)(2)(6)(7)(9)(10)(11).   
 
Both preneoplastic lesions, PanIN and IPMN, follow a sequence of events leading to 
adenocarcinoma. The tumor progression will be different depending on the preneoplastic lesion. 
Ductal adenocarcinoma more often arising in PanIN, while a mucinous adenocarcinoma 
developped more often on IPMN (1)(3)(12). However, the prognosis seems to be different 
between these two histological types of adenocarcinomas. While for the ductal adenocarcinoma 
survival at 5 years is less than 5% (5)(1), it leads about 57% for mucinous adenocarcinoma (4). 
In this study we analyze different parameters and tumor behaviour that could explain the 
difference in survival betweenthese two groups of pancreatic adenocarcinoma.  
 
3. Material and methods 
 
35 patients, (20 men and 15 women) treated by surgery for pancreatic adenocarcinoma in the 
department of visceral surgery at University Hospital of Lausanne (CHUV), between 2003 and 
2008 were selected for this study. A retrospective analysis were carried out using several 
parameters: age, gender, type of operation, histological type of tumor, preneoplastic lesions, 
TNM stage, tumor grade, lymphatic invasion, vascular invasion, neural invasion, margins status, 
adjuvant therapy and survival (DFS-disease free survival). For 23 patients the clinical follow-up 
was not available in the archives of CHUV and we have contacted their physician. The most 
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parameters have been analyzed as numerical values. Due to limited number of patients, and in 
order to perform pertinent statistical analysis, several data were regrouped. Such as, the high-
grade tumors (G2 and G3) were grouped and compared to low grade tumors (G1). The tumor 
stages T1/2 were also grouped and compared to and T3/4 stages. The IPMN lesions were 
classified as low-grade (adenoma) and high grade (borderline neoplasia and carcinoma in situ). 
The margins status were classified as margins >0,1cm and margins ≤0,1cm. 
Clinical follow-up has been analysed according to tumor-free survival, survival with disease, 
death without disease and death with disease.  
  
4.Result 
 
The follow-up in our study ranges from 1 month to 7 years, with a mean follow-up of 20 months. 
A univariate statistical analysis was conducted in order to compare the influence of each of the 
above mentioned variables in order to determine their impact on patient survival. 
After that, a multivariate analysis was performed in order to determine which of all parameters 
confounded had affected significantly the patient survival in each group (adenocarcinomas on 
PanIN and adenocarcinomas on IPMN).  
Table 2 shows distribution of all tumoral parameters analysed in our study 
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4.2  Table 2: Distribution of all tumoral parameters  
 
 Adenocarcinomas on PanIN 
(n=22) 
Adenocarcinomas on IPMN 
(n=13) 
Gender : 
Men       (n=20) 
Women (n=15) 
 
12 
10 
 
8 
5 
Age : 
<70  (n=18) 
>70  (n=17) 
 
11 
11 
 
7 
6 
PanIN1-A and B (n=25) 
PanIN 2+3 (n=33) 
16 
23 
9 
10 
IPMN Adenoma (n=9) 
IPMN Borderline+CIS (n=9) 
0 
0 
9 
9 
T1/2 stage  (n=8) 
T3/4 stage  (n=25) 
3 
19 
5 
6 
Lymph node metastases 
N+ (n=20) 
N-  (n=15) 
 
16 
6 
 
4 
9 
Metastases 
M+ (n=5) 
M-  (n=30) 
 
3 
19 
 
2 
11 
Tumor grade 
G1       (n=7) 
G2/G3 (n=28) 
 
1 
21 
 
6 
7 
Lymphatic invasion 
Yes (n=21) 
No  (n=14) 
 
17 
5 
 
4 
9 
Vascular invasion 
Yes  (n=14) 
No    (n=21) 
 
10 
12 
 
4 
9 
Perineural invasion 
Yes (n=28) 
No   (n=7) 
 
20 
2 
 
8 
5 
Margins 
<0,1cm (n=18) 
>0,1cm  (n=17) 
 
13 
9 
 
5 
8 
Adjuvant therapy 
Yes (n=19) 
No   (n=16) 
 
14 
8 
 
5 
8 
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From 35 patients involved in this study, 22 presented ductal adenocarcinomas on PanIN (Figure 
1a) and 13 adenocarcinomas on IPMN (including 6 ductal adenocarcinomas, 5 mucinous 
adenocarcinomas and 2 adenomas). (Figures 1b,1c). 
 
 
 
 
 
 
 
 
 
The patient’s mean age was 69 years, and the mean survival was 20 months. The most of 
patients (22) presented ductal adenocarcinomas developed on PanIN with a more aggressive 
behaviour, which can explains in part a mean survival at about only 20 months.  
 
 
 
 
 
 
 
 
 
Figure 1b : Ductal adenocarcinoma on IPMN 
(original magnification 8x400) 
Figure 1c : Mucinous adenocarcinom on IPMN 
(original magnification 7x400) 
 
8x400 
Figure 1a : Ductal adenocarcinoma on PanIN 
(original magnification 7x400) 
 
7x400 
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The comparative analysis of survival between adenocarcinomas on PanIN and 
adenocarcinomas on IPMN is shown in Figure1. The patients with an adenocarcinoma on IPMN 
present significantly better overall survival than those presented an adenocarcinoma developed 
on PanIN (P value =0,01).  
Figure 1 
 
8 patients presented T1/2 stage and 25 patients presented a T3/4 stage. The survival for T1/2 
group is improved as compare to T3/4 (P value=0,08) as shown in Figure 2. 
Figure 2 
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20 patients presented lymph node metastases. The survival for patients without lymph node 
metastases is improved as compared to patients with lymph node metastases  (P value = 0,03) 
as shown in Figure 3 . 
Figure 3 
 
The tumor grade is analyzed by comparing G1 against G2/3 as shown in Figure 4. 7 patients 
presented G1 grade, while 28 patients presented G2/3 grade. As expected, the overall survival 
is higher in low-grade tumor group (G1) as compared to high-grade group (G2/3) (P value= 
0,06) .   
Figure 4 
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14 patients presented adenocarcinoma with vascular invasion. The survival for patients without 
vascular invasion is improved as compared to patients with vascular invasion (P value=0,04) as 
shown in Figure 5. 
Figure 5 
 
21 patients presented adenocarcinoma with lymphatic invasions. The survival for patients 
without lymphatic invasion is improved as compared to patients with lymphatic invasion (P 
value=0,01) as shown in Figure 6. 
Figure 6 
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28 patients presented adenocarcinoma with perineural invasion. The survival for patients without 
perineural invasion is improved as compared to patients with perineural invasion (P value = 
0,23) as shown in Figure 7.  
Figure 7 
 
18 patients presented resection margins <0,1/cm. The survival for patients with margins >0,1cm 
is improved as compared to patients with margins <0,1cm/(P value=0,752, data not shown) 
 
9 of 35 patients beneficed the adjuvant chemotherapy. In our collective, the survival was 
improved for patients without chemotherapy as compared to patients with chemotherapy. (P 
value =0,959, data not shown). 
 
The distant metastases analysis is not presented here, as the number of patients with distant 
metastases was very limited (only 5 of 35) to conduct a pertinent statistical analysis. 
 
The multivariate analysis revealed one parameter influencing significantly the survival. It appears 
that vascular invasion, compared to all other factors, is associated to poor survival (P 
value=0,03).  
14 of 35 patients involved in our study presented vascular invasion. Between them, 10 patients 
(45%) presented adenocarcinoma on PanIN and only 4 patients (30%) presented 
adenocarcinoma on IPMN. As the vascular invasion will promote the development of distant 
disease, this distribution should explain in part a mean survival at about 20 months in our 
collective.   
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5. Discussion 
 
Initially we aimed to perform a comparative analysis between ductal and mucinous subtype of 
pancreatic adenocarcinomas. However, the number of patients with purely mucinous 
adenocarcinomas was limited to conduct a statistical analysis. That's why we decide to perform 
a comparative analysis between adenocarcinomas developed on PanIN and adenocarcinomas 
developed on IPMN. 
The both type of pancreatic adenocarcinomas affect an elderly population, with a mean age of 
69 years. The poor prognosis is most often observed in group of adenocarcinomas developed 
on pre-existing PanIN lesions. The average survival was approximately 27% at 20 months. 
Our study reflects that adenocarcinomas (ductal or mucinous) developed on IPMN are 
associated with better survival and prognosis than ductal adenocarcinomas arising in PanIN 
lesions. 
This fact should be in part explains by different molecular events and alterations during tumour 
progression. 
The adenocarcinoma of ductal type develops along the adenoma-carcinoma sequence. During 
this transformation several genetic alterations occur. The earliest and most frequent genetic 
alterations in PanIN lesions are the inactivation of K-RAS and telomerase shortening, while the 
inactivation of p53, SMAD4 and BRCA2 occurs more often with progression into PanIN2 and 
PanIN3 lesions (1)(2). The SMAD4 inactivation, usually found in PanIN, is rare in IPMN.  The 
major molecular alterations are shown in Figure 8. 
 
Figure 8: Correlation between proliferative activity and dysplasia in pancreatic intraepithelial 
neoplasia (PanIN). Ref: Walter M Klein, Ralph H Hruban, Andres J P Klein-Szanto and Robb E Wilentz 
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Actually, the sequence of genetic alterations for IPMN is less well known. 1/3 of IPMN present 
an alteration of the gene STK11/LKB1, while this it is unusual in the PanIN (1).  
We can therefore make the assumption that these different genetic alterations may influence the 
evolution in ductal or mucinous types adenocarcinomas and the degree of tumor 
aggressiveness. 
 
Another explanation of difference in suvival and behaviour between these two histological 
entities is related to their morphological characteristics. 
Adenocarcinomas developed on IPMN are usually associated with cystic structures easily visible 
on imaging. Therefore these lesions should be potentially detected and treated at an earlier 
stage than conventional ductal adenocarcinomas developed on PanIN lesions. This fact should 
also explain a difference in survival between adenocarcinomas on PanIN and adenocarcinomas  
on IPMN.  This fact is also supported in our study. The analysis of TNM stage shows that only 3 
(13%) adenocarcinomas developed on PanIN are at T1/2 stage, while in group of 
adenocarcinomas developed on IPMN they represent 5 (38%) of adenocarcinomas.  
The closely similar results were found after analysis of lymph node metastases. 9 (69%) of 
adenocarcinomas developed on IPMN were free of lymph node metastases, while only 6 (27%) 
of adenocarcinomas developed on PanIN do not present metastatic lymph node disease.  
 
In our study 19 of 35 patients have been treated with adjuvant chemotherapy. It represents 14 
(63%) of adenocarcinomas developed on PanIN, and only 5 (38%) of adenocarcinomas 
developped on IPMN. Usually it is rather for advanced cancers, such as adenocarcinomas on 
PanIN, that an adjuvant chemotherapy is applied. As the most of the patients with 
adenocarcinomas developed on IPMN were diagnosed at an earlier stage they were not treated 
with chemotherapy.  
Concerning the distant metastatic disease, our study is not completely in agreement with data 
reported in literature (1)(5). In the most of cases pancreatic adenocarcinomas are diagnosed 
with metastatic disease at initial presentation. In our study only 5 (14%) of 35 patients presented 
distant metastases. However this parameter is not considered in our statistical analysis due to 
the limited number of patients.    
This study shows a difference in survival between adenocarcinomas developed on PanIN and 
adenocarcinomas developed on IPMN (including both, ductal and mucinous type). It is very 
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interesting to note that both, mucinous and ductal adenocarcinomas developed on IPMN, are 
associated with a better survival as compared to ductal adenocarcinomas developed on PanIN. 
Indeed, the IPMN lesions are different from PanIN lesions, due to their topography, morphology 
but also at the molecular level. These differences may in part explain the differences in 
behaviour and improved survival in patients with adenocarcinomas developed on IPMN. It is 
known that different IPMN subtypes will evolves toward mucinous or ductal adenocarcinoma, but 
the pathways is not still well known.  
It will be interesting to study and compare the differences at the molecular level, firstly between 
ductal and mucinous adenocarcinomas developed on IPMN and secondly between ductal 
adenocarcinomas developed on IPMN and ductal adenocarcinomas developed on PanIN in 
order to predict tumour progression and prognosis. 
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